Floatz logo

Ribociclib

Diffuse Midline Glioma, H3 K27M-Mutant

Nationwide Children's HospitalSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Diffuse Midline Glioma, H3 K27M-Mutant cohort.

Asset / SponsorPhaseRating
Olutasidenib
Rigel Pharmaceuticals
Phase 2CCC
Everolimus
Nationwide Children's Hospital
Phase 2CCC
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CC
Pegargiminase
Sabine Mueller, MD, PhD
Phase 1/2CC
gsk1120212
St. Jude Children's Research Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

Ribociclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
HR+/HER2- Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →